In the development of new drugs products,especially the development of traditional Chinese medicine active ingredients,solubility and oral bioavailability are the main factors which are restricting the development of ...In the development of new drugs products,especially the development of traditional Chinese medicine active ingredients,solubility and oral bioavailability are the main factors which are restricting the development of new drugs,whereas the physicochemical properties of active ingredients are the key element to affecting these factors.Pharmaceutical cocrystal provides an excellent opportunity to develop new drugs with excellent physical and chemical properties such as melting point,solubility,stability and bioavailability while retaining the pharmacological properties of individuals active pharmaceutical ingredients among pharmaceutical cocrystal compounds.Traditional Chinese herbal medicine has the characteristics of multiple pathways and multiple targets,mainly because it contains many active ingredients,like cocrystals thereof with many components.The active ingredients extracted from traditional Chinese herbal medicine have a wide range of pharmacological activities,but most of the active ingredients affect the development of traditional Chinese medicine active ingredients due to their physical and chemical properties such as solubility.Traditional Chinese medicine pharmaceutical cocrystals can not only improve the physical and chemical properties of drugs without changing the internal structure of drugs,so as to provide a new scheme for the development of traditional Chinese medicine active ingredients.This paper reviews the research progress of active ingredients of traditional Chinese medicine pharmaceutical cocrystal.The preparation methods of cocrystals are summarized and the advantages of cocrystals are illustrated with examples.展开更多
Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global ...Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.展开更多
A high-performance liquid chromatographic method was applied to the determination of stachydrine hydrochloride concentration in TJF granule (Chinese name: Tiao-Jing-Fang), using a mobile phase of methanol-acetonitrile...A high-performance liquid chromatographic method was applied to the determination of stachydrine hydrochloride concentration in TJF granule (Chinese name: Tiao-Jing-Fang), using a mobile phase of methanol-acetonitrile (50:50, v/v) by the Agilent Kromasi NH2 column (250 mm × 4.6 mm, 5 μm, S/N: 22N25110). Detection wavelength was 201 nm. The result revealed good linearity of stachydrine hydrochloride and was obtained within the range of 0.20 - 1.98 μg/mL (R = 0.9995). The average recovery was 97.01%;the relative standard deviation (RSD) was 0.19%. To the best of our knowledge, this is the first report dedicated to the determination of stachydrine hydrochloride by the evaporative light scattering detector-high-performance liquid chromatographic (ELSD-HPLC) method.展开更多
背景:如何修复骨缺损一直以来是临床难题,中药有效成分在骨修复方面具有良好的生物活性与治疗效果,将中药有效成分与组织工程材料相结合在骨修复领域具有广阔的前景。不同中药有效成分与支架的组合在作用关系方面具有相似之处。目的:搜...背景:如何修复骨缺损一直以来是临床难题,中药有效成分在骨修复方面具有良好的生物活性与治疗效果,将中药有效成分与组织工程材料相结合在骨修复领域具有广阔的前景。不同中药有效成分与支架的组合在作用关系方面具有相似之处。目的:搜集常见的中药有效成分与支架材料组合的案例,基于七情配伍的启发将组织工程支架与中药有效成分类比为产生配伍关系的两类中药,以二者的作用关系为纲进行归纳总结。方法:检索1998年1月至2024年1月Pub Med和中国知网数据库中发表的相关文献,英文检索词:“traditional Chinese medicine,Chinese medicine,traditional Chinese medicine monomers,bone defect,bone repair,bone tissue engineering,tissue engineering,scaffold”,中文检索词:“中药,中药有效成分,中药单体,骨组织工程,骨组织工程支架,支架,组织工程,骨缺损,骨修复”,最终纳入88篇文献进行综述分析。结果与结论:(1)组织工程支架材料与中药有效成分各自均在骨修复领域有广泛的运用,二者在成骨方面优势明显但仍有许多缺陷,许多研究致力于将二者制备成复合材料,希望通过二者间的相互作用发挥减毒增效作用。(2)一些药物与材料在成骨、抗菌、促血管生成方面能互相促进,增强原有的效果,受到传统方剂配伍观念的启发,文章将其归纳为“相须”关系,并举实例佐证。(3)一些药物能提高材料的强度,而某些材料能对负载于其上的药物实现缓释控释效果、增加载药量与稳定性,或是进行靶向递送,文章将这种单方面的提升效果归纳为“相使”关系。(4)一些中药与材料搭配使用能减少对方的毒副反应,文章将这种减毒关系归纳为“相畏相杀”。(5)文章得出了一个由七情配伍关系启发、基于作用关系分类的关于中药复合支架的全新视角,将中药传统观念引入组织工程领域,为后续复合支架的研究者提供新的研究思路,并在选材搭配方面提供一定的便利。展开更多
背景:静电纺丝多孔纳米纤维是一种具有优良性能和可设计性的材料,将传统中药与其联合构建新型中药控释系统是实现中药的控制释放和提高生物利用度的有效途径,具有广阔应用前景。目的:综述静电纺丝中药控释系统的构建方法及其在医学领域...背景:静电纺丝多孔纳米纤维是一种具有优良性能和可设计性的材料,将传统中药与其联合构建新型中药控释系统是实现中药的控制释放和提高生物利用度的有效途径,具有广阔应用前景。目的:综述静电纺丝中药控释系统的构建方法及其在医学领域相关研究进展。方法:以“静电纺丝,中药,药物载体,释药系统,组织工程,敷料”为中文检索词,以“electrospinning,traditional Chinese medicine,drug carrier,drug delivery system,tissue engineering,dressing”为英文检索词,检索中国知网、PubMed和Web of Science数据库的关于静电纺丝中药控释系统的研究应用文献,检索时间范围为2013-2023年,最终纳入62篇文献进行综述分析。结果与结论:①构建电纺多孔纤维中药控释系统的关键要素为基质材料、中药成分和载药方式。②电纺多孔纤维中药控释系统的构建可依据应用场景和治疗目的进行,首先选定中药成分种类,然后依据药物特性选择与其适配的聚合物基体及溶液,最后依据释药需求设计纤维结构并采用适宜的载药方式。③目前在电纺纤维中药控释系统中所应用的药剂以易制备纺丝溶液的植物中药提取物为主,缺少动物中药和矿物中药的系统研究。④共混载药是研究应用最多的载药方式,且通过对溶液理化性质的优化和负载物质多样性的选择不断扩展其释药特性和适应场景;同轴、多轴及顺序纺丝等载药方式可以制备具有多层成分性质不同的复合纤维,具有广阔发展前景。⑤电纺纤维中药控释系统早期应用集中于医用敷料方面,利用中药活性成分的抗菌止血功能,近年来发现中药某些成分能促进细胞黏附增殖分化,开启了组织工程领域的探索研究。⑥目前对电纺多孔纤维中药控释系统的研究主要集中在对负载材料、工艺、理化性能、生物性能的表征和优化上,而对机制的研究较少,其在临床中的应用尚未普及,在体内的不良反应尚不明了,对其降解行为与释药行为的相互影响也缺乏研究。⑦未来研究中需要考虑:通过改善中药与纺丝溶剂的理化性能和加大中药活性成分的提纯以扩大非植物中药的应用范围,对中药成分的治疗效果和作用机制进行全面研究,并阐明控释系统的降解行为与释药行为的相互影响规律,在更准确的机制下实现中药与电纺纳米纤维更完美的联合和应用。展开更多
基金The National Natural Science Foundation of China(No.81973977,No.81273872)the Fundamental Research Funds for the Central Universities(2021JCXK02)supported this study.
文摘In the development of new drugs products,especially the development of traditional Chinese medicine active ingredients,solubility and oral bioavailability are the main factors which are restricting the development of new drugs,whereas the physicochemical properties of active ingredients are the key element to affecting these factors.Pharmaceutical cocrystal provides an excellent opportunity to develop new drugs with excellent physical and chemical properties such as melting point,solubility,stability and bioavailability while retaining the pharmacological properties of individuals active pharmaceutical ingredients among pharmaceutical cocrystal compounds.Traditional Chinese herbal medicine has the characteristics of multiple pathways and multiple targets,mainly because it contains many active ingredients,like cocrystals thereof with many components.The active ingredients extracted from traditional Chinese herbal medicine have a wide range of pharmacological activities,but most of the active ingredients affect the development of traditional Chinese medicine active ingredients due to their physical and chemical properties such as solubility.Traditional Chinese medicine pharmaceutical cocrystals can not only improve the physical and chemical properties of drugs without changing the internal structure of drugs,so as to provide a new scheme for the development of traditional Chinese medicine active ingredients.This paper reviews the research progress of active ingredients of traditional Chinese medicine pharmaceutical cocrystal.The preparation methods of cocrystals are summarized and the advantages of cocrystals are illustrated with examples.
文摘Within the public health sector of Hong Kong(China),there is a consensus around the important role of traditional Chinese medicines.For Hong Kong(China)to play a bridging role to bring Chinese medicines to the global market requires a concerted effort from the government,academic institutes and industries.The release of the final version of the European Medicines Agencies guidance document,which details the acceptance of minimum requirements to nonclinical package in bibliographical applications,grants the opportunity for well-established and traditional herbal medicines to demonstrate an‘acceptable safe’status for registration in the European Union.It is anticipated that this minimum nonclinical package can be applied to demonstrate the safe use of many traditional Chinese medicines regardless of their eligibility to be registered under the simplified procedure within the European Union.This paper conceptualizes an integration of a simplified evaluation route for eligible proprietary Chinese medicines(pCm)with long history of use into the existing drug regulatory framework in Hong Kong(China).Such integration utilizing the minimum nonclinical package,based on bibliographical data or expert report,as proof of evidence to demonstrate safety for pCm with long history of use requires less demand in scientific resources.With Hong Kong(China)conducting‘first hand’review for eligible pCm,it provides an option for overseas and local pharmaceutical companies to register their products in Hong Kong(China)without the need to rely on issuance of Certificate of Pharmaceutical Product from other countries.This could bring eligible pCm with long history of use to reach international risk-based standard and to be marketed globally as‘medicines’to reach their full therapeutic potential.An important process to positioning Hong Kong(China)to compete with other countries in promoting importation and exportation of pCm to better serve the global health.
文摘A high-performance liquid chromatographic method was applied to the determination of stachydrine hydrochloride concentration in TJF granule (Chinese name: Tiao-Jing-Fang), using a mobile phase of methanol-acetonitrile (50:50, v/v) by the Agilent Kromasi NH2 column (250 mm × 4.6 mm, 5 μm, S/N: 22N25110). Detection wavelength was 201 nm. The result revealed good linearity of stachydrine hydrochloride and was obtained within the range of 0.20 - 1.98 μg/mL (R = 0.9995). The average recovery was 97.01%;the relative standard deviation (RSD) was 0.19%. To the best of our knowledge, this is the first report dedicated to the determination of stachydrine hydrochloride by the evaporative light scattering detector-high-performance liquid chromatographic (ELSD-HPLC) method.
文摘背景:如何修复骨缺损一直以来是临床难题,中药有效成分在骨修复方面具有良好的生物活性与治疗效果,将中药有效成分与组织工程材料相结合在骨修复领域具有广阔的前景。不同中药有效成分与支架的组合在作用关系方面具有相似之处。目的:搜集常见的中药有效成分与支架材料组合的案例,基于七情配伍的启发将组织工程支架与中药有效成分类比为产生配伍关系的两类中药,以二者的作用关系为纲进行归纳总结。方法:检索1998年1月至2024年1月Pub Med和中国知网数据库中发表的相关文献,英文检索词:“traditional Chinese medicine,Chinese medicine,traditional Chinese medicine monomers,bone defect,bone repair,bone tissue engineering,tissue engineering,scaffold”,中文检索词:“中药,中药有效成分,中药单体,骨组织工程,骨组织工程支架,支架,组织工程,骨缺损,骨修复”,最终纳入88篇文献进行综述分析。结果与结论:(1)组织工程支架材料与中药有效成分各自均在骨修复领域有广泛的运用,二者在成骨方面优势明显但仍有许多缺陷,许多研究致力于将二者制备成复合材料,希望通过二者间的相互作用发挥减毒增效作用。(2)一些药物与材料在成骨、抗菌、促血管生成方面能互相促进,增强原有的效果,受到传统方剂配伍观念的启发,文章将其归纳为“相须”关系,并举实例佐证。(3)一些药物能提高材料的强度,而某些材料能对负载于其上的药物实现缓释控释效果、增加载药量与稳定性,或是进行靶向递送,文章将这种单方面的提升效果归纳为“相使”关系。(4)一些中药与材料搭配使用能减少对方的毒副反应,文章将这种减毒关系归纳为“相畏相杀”。(5)文章得出了一个由七情配伍关系启发、基于作用关系分类的关于中药复合支架的全新视角,将中药传统观念引入组织工程领域,为后续复合支架的研究者提供新的研究思路,并在选材搭配方面提供一定的便利。
文摘背景:静电纺丝多孔纳米纤维是一种具有优良性能和可设计性的材料,将传统中药与其联合构建新型中药控释系统是实现中药的控制释放和提高生物利用度的有效途径,具有广阔应用前景。目的:综述静电纺丝中药控释系统的构建方法及其在医学领域相关研究进展。方法:以“静电纺丝,中药,药物载体,释药系统,组织工程,敷料”为中文检索词,以“electrospinning,traditional Chinese medicine,drug carrier,drug delivery system,tissue engineering,dressing”为英文检索词,检索中国知网、PubMed和Web of Science数据库的关于静电纺丝中药控释系统的研究应用文献,检索时间范围为2013-2023年,最终纳入62篇文献进行综述分析。结果与结论:①构建电纺多孔纤维中药控释系统的关键要素为基质材料、中药成分和载药方式。②电纺多孔纤维中药控释系统的构建可依据应用场景和治疗目的进行,首先选定中药成分种类,然后依据药物特性选择与其适配的聚合物基体及溶液,最后依据释药需求设计纤维结构并采用适宜的载药方式。③目前在电纺纤维中药控释系统中所应用的药剂以易制备纺丝溶液的植物中药提取物为主,缺少动物中药和矿物中药的系统研究。④共混载药是研究应用最多的载药方式,且通过对溶液理化性质的优化和负载物质多样性的选择不断扩展其释药特性和适应场景;同轴、多轴及顺序纺丝等载药方式可以制备具有多层成分性质不同的复合纤维,具有广阔发展前景。⑤电纺纤维中药控释系统早期应用集中于医用敷料方面,利用中药活性成分的抗菌止血功能,近年来发现中药某些成分能促进细胞黏附增殖分化,开启了组织工程领域的探索研究。⑥目前对电纺多孔纤维中药控释系统的研究主要集中在对负载材料、工艺、理化性能、生物性能的表征和优化上,而对机制的研究较少,其在临床中的应用尚未普及,在体内的不良反应尚不明了,对其降解行为与释药行为的相互影响也缺乏研究。⑦未来研究中需要考虑:通过改善中药与纺丝溶剂的理化性能和加大中药活性成分的提纯以扩大非植物中药的应用范围,对中药成分的治疗效果和作用机制进行全面研究,并阐明控释系统的降解行为与释药行为的相互影响规律,在更准确的机制下实现中药与电纺纳米纤维更完美的联合和应用。